BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36107485)

  • 21. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
    Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
    Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
    Plassmeier L; Knoop R; Waldmann J; Kesselring R; Buchholz M; Fichtner-Feigl S; Bartsch DK; Fendrich V
    Langenbecks Arch Surg; 2013 Oct; 398(7):989-96. PubMed ID: 23989613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Li JJX; Ni SYB; Tsang JYS; Chan WY; Hung RKW; Lui JWH; Ng SWY; Shum LK; Tang YF; Tse GM
    Histopathology; 2024 Apr; 84(5):810-821. PubMed ID: 38192219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
    Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
    Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
    Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
    Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury.
    Fendrich V; Jendryschek F; Beeck S; Albers M; Lauth M; Esni F; Heeger K; Dengler J; Slater EP; Holler JPN; Baier A; Bartsch DK; Waldmann J
    Oncogene; 2018 Apr; 37(14):1845-1856. PubMed ID: 29367759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
    Pakola S; Quixabeira DCA; Kudling TV; Clubb JHA; Grönberg-Vähä-Koskela S; Basnet S; Jirovec E; Arias V; Haybout L; Heiniö C; Santos JM; Cervera-Carrascon V; Havunen R; Anttila M; Hemminki A
    Front Immunol; 2023; 14():1171083. PubMed ID: 37475863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer.
    Goetze RG; Buchholz SM; Ou N; Zhang Q; Patil S; Schirmer M; Singh SK; Ellenrieder V; Hessmann E; Lu QB; Neesse A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31181844
    [No Abstract]   [Full Text] [Related]  

  • 32. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker?
    Merlo I; Ardiles V; Sanchez-Clariá R; Fratantoni E; de Santibañes E; Pekolj J; Mazza O; de Santibañes M
    J Gastrointest Cancer; 2023 Jun; 54(2):580-588. PubMed ID: 35653056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study.
    Zhang H; Chen J; Bai J; Zhang J; Huang S; Zeng L; Zhou P; Shen Q; Yin T
    Int J Surg; 2024 May; 110(5):2679-2691. PubMed ID: 38489548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
    Chen Y; Yan H; Wang Y; Shi Y; Dai G
    Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression.
    Takahashi R; Macchini M; Sunagawa M; Jiang Z; Tanaka T; Valenti G; Renz BW; White RA; Hayakawa Y; Westphalen CB; Tailor Y; Iuga AC; Gonda TA; Genkinger J; Olive KP; Wang TC
    Gut; 2021 Feb; 70(2):330-341. PubMed ID: 32393543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
    Hessmann E; Patzak MS; Klein L; Chen N; Kari V; Ramu I; Bapiro TE; Frese KK; Gopinathan A; Richards FM; Jodrell DI; Verbeke C; Li X; Heuchel R; Löhr JM; Johnsen SA; Gress TM; Ellenrieder V; Neesse A
    Gut; 2018 Mar; 67(3):497-507. PubMed ID: 28077438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
    Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
    Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.